Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin benefit

This article was originally published in The Tan Sheet

Executive Summary

Findings of a multicenter follow-up study of "vascular complications" in 1,007 European and Israeli atrial fibrillation patients who had suffered minor strokes suggest that aspirin use could prevent "40 vascular events each year for every 1,000 treated patients." In a comparison of 300 mg aspirin daily, anticoagulant therapies and placebo published in the Nov. 20 Lancet, Peter Koudstall, MD, University Hospital Rotterdam Dijkzigt, et al. found that anticoagulant therapy was the most effective at preventing events (with an estimated 90 in 1,000 prevented), but that aspirin was a "safe, though less effective alternative where anticoagulation is counterindicated".
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel